FiercePharma  Aug 13  Comment 
Biosimilars promise huge potential, with estimates for this decade running from $35 billion to $200 billion and growing exponentially from there. And of course the U.S., being the world's largest pharma market, presents the greatest potential,...
FiercePharma  Aug 11  Comment 
The European Commission has approved Bayer's Eylea (aflibercept) for the treatment of diabetic macular edema, the most common cause of vision loss among people with diabetes.
newratings.com  Aug 11  Comment 
Novartis to showcase heart failure leadership at ESC Congress 2014 with results on new first of its type medicine LCZ696 Novartis International AG / Novartis to showcase heart failure leadership at ESC Congress 2014 with results on new first of...
FiercePharma  Aug 8  Comment 
Novartis has failed again to convince a federal judge to boot a Department of Justice kickbacks case against it that claims the Swiss drugmaker showered pharmacies with discounts and rebates to boost sales of two drugs.
Clusterstock  Aug 8  Comment 
By Jonathan Stempel NEW YORK (Reuters) - A Manhattan federal judge on Thursday said the U.S. Department of Justice may pursue most of its lawsuit accusing Novartis AG of civil fraud for allegedly using kickbacks to boost sales of drugs covered...
newratings.com  Aug 5  Comment 
NOVARTIS FINANCE S.A. / Novartis to showcase heart failure leadership at ESC Congress 2014 with results on new first of its type medicine LCZ696 . Processed and transmitted by NASDAQ OMX Corporate Solutions. The issuer is solely responsible for...
FierceBiotech  Aug 5  Comment 
In the pharma business, you're only as good as your next big blockbuster. And in Novartis' case, the next big cardio blockbuster--LCZ696--looks very good, indeed.
Market Intelligence Center  Aug 4  Comment 
After closing Friday at $86.90, Novartis AG (NVS) presents an attractive opportunity to get a 3.66% return in just 166 days, which is an annualized return of 8.04% (for comparison purposes only). To enter this trade, sell one Jan. '15 $85.00 call...
FiercePharma  Jul 31  Comment 
Facing its second scandal in as many months, Novartis' Japanese unit has issued an apology for failing to disclose side effects of its drugs Tasigna and Gleevec, which are used to treat leukemia.


Fuerralz? That's marvelously good to know.

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki